Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed non-small cell lung cancer (NSCLC)
Recurrent AND/OR Stage IIIB with pleural or pericardial effusion OR Stage IV Must have at
least one bidimensionally measurable lesion Must be HER2 positive (1-3+) Brain metastases
allowed, if symptoms controlled and not requiring steroids Prior/Concurrent Therapy--
Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for NSCLC Endocrine
therapy: No concurrent steroids Radiotherapy: At least 2 weeks since prior radiotherapy
Surgery: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:
Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminases no greater
than 5 times upper limit of normal Renal: Creatinine no greater than 2 mg/dL
Cardiovascular: No uncontrolled angina pectoris and arrhythmias No myocardial infarction
within past 3 months No uncompensated congestive heart failure Ejection fraction at least
45% Other: No active infections Not pregnant or nursing Fertile patients must use
effective contraception HIV negative No other active malignancies No evidence of
peripheral sensory neuropathy of at least grade 2